Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Andritz, Marinomed, Valneva, Pierer Mobility, Palfinger, Wolftank Adisa (12/04/2021)

18.04.2021

Andritz: International technology Group Andritz has successfully started up a new 500 t/d Herb chemical recovery boiler at Kuantum Papers Limited in Saila Khurd, Hoshiapur district in the state of Punjab, India. The boiler is designed to handle a mixture of hardwood and agro-based black liquor and enables environmentally friendly and more energy-efficient operation compared to a conventional boiler with direct contact evaporator. Thus, the mill’s pulp production as well as the power-to-heat-ratio are substantially increased. The boiler also features a unique vertical air system to minimize air emissions.
Andritz: weekly performance: -1.21%

Marinomed: Marinomed Biotech AG, an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that out of the initially enrolled 64 patients, all 62 patients included in the treatment cycles have now concluded the Phase II clinical trial evaluating Tacrosolv eye drops in allergic rhinoconjunctivitis, i. e. hay fever affecting both the eyes and nose. The randomized, placebo controlled, double-blind phase II clinical trial was conducted at the Vienna Challenge Chamber (Austria) to assess safety and efficacy of two different dosages of Tacrosolv in a crossover design. Positive results provided, the Company plans to extend the ophthalmic use of Tacrosolv to further indications beyond allergic symptoms such as dry eye disease (keratoconjunctivitis sicca) and other types of ocular inflammation. “We are very pleased to conclude the active part of our phase II Tacrosolv. We are confident that the results will support our hypothesis that Tacrosolv is the first formulation of this highly potent immunosuppressant that allows for its use as an effective therapy in ocular inflammation,” said Eva Prieschl-Grassauer, Chief Scientific Officer of Marinomed. “Formulated with Marinosolv, we could achieve a more than 200-fold higher solubility compared to water enabling the use of tacrolimus in eye drops. Moreover, our formulation has a high local bioavailability – characteristics we have seen for several Marinosolv formulations so far.”
Marinomed Biotech: weekly performance: -2.14%

Valneva: Valneva SE, an Austrian/French specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its American Depositary Shares, representing ordinary shares, in the United States, and a concurrent offering of its ordinary shares in certain jurisdictions outside of the United States. All securities to be sold in the Global Offering will be offered by the Company. Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. are acting as joint bookrunners for the Global Offering. Namsen Capital is acting as Valneva’s capital markets advisor. Futher, the company announced, that it has completed recruitment for the pivotal Phase 3 trial, VLA1553-301, of its single-shot chikungunya vaccine candidate, VLA1553. The sponsor of the first chikungunya vaccine Biologics License Application (BLA) to be approved in the U.S. will be eligible to receive a Priority Review Voucher (PRV).
Valneva: weekly performance: 2.61%

Pierer Mobility: In the first quarter of the 2021 financial year, the Pierer Mobility Group generated record unit sales and revenues, driven by high global demand for powered two-wheelers (PTWs). Revenues of Euro 509 mn were generated in this period (Q1 2020: Euro 278.9 mn), representing an increase of 82% compared to the previous year. The company increased revenue guidance for the 2021 financial year 2021 to Euro 1,850 mn to Euro 1,950 mn (previous revenue guidance 2021: 1,800 mn to 1,900 mn). A total of 106,453 vehicles (Q1 2020: 59,168) were sold worldwide, including 87,197 motorcycles (Q1 2020: 49,869 units) of the KTM, Husqvarna and Gasgas brands and 19,256 e-bikes (Q1 2020: 9,299 units) of the R Raymon and Husqvarna brands. In total, this represents an increase of 80% over the same period of the previous year. This is associated with a significant increase in global market shares. In Europe, 53,971 motorcycles and e-bikes were sold during the period (+79% over the same period of the previous year). Growth was particularly strong in North America, where 12,637 motorcycles were sold, up 145% over the same period of the previous year. A similar trend was seen in Australia, with an increase of 109% and a total of 4,357 units sold. In India, despite the ongoing difficult conditions related to the COVID-19 crisis, sales increased by 24% to 20,712 motorcycles.
Pierer Mobility AG: weekly performance: 2.00%

Palfinger: Based on the current forecast, the Executive Board of lifting solutions producer Palfinger AG expects revenue for Q1 of 2021 to exceed revenue of the same period in 2020 (Euro 393.2 mn), as already announced at the beginning of February. Thanks to a strong product mix as well as lower structural costs, the EBIT margin during the first three months of 2021 will be significantly higher than the previous year at around 10 percent (Q1 2020: 8.0 percent). For the full year 2021, management aims to exceed the results obtained in 2019 (revenue Euro 1.75 bn, EBIT Euro 149 mn), which was a record year.
Palfinger: weekly performance: 8.13%

Wolftank-Adisa: The Executive Board of Wolftank Adisa Holding AG resolved to increase the share capital by issuing up to 125,000 new no-par value bearer shares at an issue price of Euro 32.00 per share by partially utilizing the existing authorized capital against cash contribution. The use of funds will serve the further growth of the Group and the strengthening of equity. Wolftank-Adisa  is the parent company of an international group of companies focusing on environmental protection services for polluted soils, facilities and waters, remediation and monitoring of (large) tank facilities, as well as full-service engineering services for (LNG and hydrogen) tank facilities.
Wolftank-Adisa: weekly performance: 0.00%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (12/04/2021)


Partners









latest 21st Austria

21st Austria weekly - Andritz, Marinomed, Valneva, Pierer Mobility, Palfinger, Wolftank Adisa (12/04/2021)


18.04.2021


Andritz: International technology Group Andritz has successfully started up a new 500 t/d Herb chemical recovery boiler at Kuantum Papers Limited in Saila Khurd, Hoshiapur district in the state of Punjab, India. The boiler is designed to handle a mixture of hardwood and agro-based black liquor and enables environmentally friendly and more energy-efficient operation compared to a conventional boiler with direct contact evaporator. Thus, the mill’s pulp production as well as the power-to-heat-ratio are substantially increased. The boiler also features a unique vertical air system to minimize air emissions.
Andritz: weekly performance: -1.21%

Marinomed: Marinomed Biotech AG, an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that out of the initially enrolled 64 patients, all 62 patients included in the treatment cycles have now concluded the Phase II clinical trial evaluating Tacrosolv eye drops in allergic rhinoconjunctivitis, i. e. hay fever affecting both the eyes and nose. The randomized, placebo controlled, double-blind phase II clinical trial was conducted at the Vienna Challenge Chamber (Austria) to assess safety and efficacy of two different dosages of Tacrosolv in a crossover design. Positive results provided, the Company plans to extend the ophthalmic use of Tacrosolv to further indications beyond allergic symptoms such as dry eye disease (keratoconjunctivitis sicca) and other types of ocular inflammation. “We are very pleased to conclude the active part of our phase II Tacrosolv. We are confident that the results will support our hypothesis that Tacrosolv is the first formulation of this highly potent immunosuppressant that allows for its use as an effective therapy in ocular inflammation,” said Eva Prieschl-Grassauer, Chief Scientific Officer of Marinomed. “Formulated with Marinosolv, we could achieve a more than 200-fold higher solubility compared to water enabling the use of tacrolimus in eye drops. Moreover, our formulation has a high local bioavailability – characteristics we have seen for several Marinosolv formulations so far.”
Marinomed Biotech: weekly performance: -2.14%

Valneva: Valneva SE, an Austrian/French specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its American Depositary Shares, representing ordinary shares, in the United States, and a concurrent offering of its ordinary shares in certain jurisdictions outside of the United States. All securities to be sold in the Global Offering will be offered by the Company. Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. are acting as joint bookrunners for the Global Offering. Namsen Capital is acting as Valneva’s capital markets advisor. Futher, the company announced, that it has completed recruitment for the pivotal Phase 3 trial, VLA1553-301, of its single-shot chikungunya vaccine candidate, VLA1553. The sponsor of the first chikungunya vaccine Biologics License Application (BLA) to be approved in the U.S. will be eligible to receive a Priority Review Voucher (PRV).
Valneva: weekly performance: 2.61%

Pierer Mobility: In the first quarter of the 2021 financial year, the Pierer Mobility Group generated record unit sales and revenues, driven by high global demand for powered two-wheelers (PTWs). Revenues of Euro 509 mn were generated in this period (Q1 2020: Euro 278.9 mn), representing an increase of 82% compared to the previous year. The company increased revenue guidance for the 2021 financial year 2021 to Euro 1,850 mn to Euro 1,950 mn (previous revenue guidance 2021: 1,800 mn to 1,900 mn). A total of 106,453 vehicles (Q1 2020: 59,168) were sold worldwide, including 87,197 motorcycles (Q1 2020: 49,869 units) of the KTM, Husqvarna and Gasgas brands and 19,256 e-bikes (Q1 2020: 9,299 units) of the R Raymon and Husqvarna brands. In total, this represents an increase of 80% over the same period of the previous year. This is associated with a significant increase in global market shares. In Europe, 53,971 motorcycles and e-bikes were sold during the period (+79% over the same period of the previous year). Growth was particularly strong in North America, where 12,637 motorcycles were sold, up 145% over the same period of the previous year. A similar trend was seen in Australia, with an increase of 109% and a total of 4,357 units sold. In India, despite the ongoing difficult conditions related to the COVID-19 crisis, sales increased by 24% to 20,712 motorcycles.
Pierer Mobility AG: weekly performance: 2.00%

Palfinger: Based on the current forecast, the Executive Board of lifting solutions producer Palfinger AG expects revenue for Q1 of 2021 to exceed revenue of the same period in 2020 (Euro 393.2 mn), as already announced at the beginning of February. Thanks to a strong product mix as well as lower structural costs, the EBIT margin during the first three months of 2021 will be significantly higher than the previous year at around 10 percent (Q1 2020: 8.0 percent). For the full year 2021, management aims to exceed the results obtained in 2019 (revenue Euro 1.75 bn, EBIT Euro 149 mn), which was a record year.
Palfinger: weekly performance: 8.13%

Wolftank-Adisa: The Executive Board of Wolftank Adisa Holding AG resolved to increase the share capital by issuing up to 125,000 new no-par value bearer shares at an issue price of Euro 32.00 per share by partially utilizing the existing authorized capital against cash contribution. The use of funds will serve the further growth of the Group and the strengthening of equity. Wolftank-Adisa  is the parent company of an international group of companies focusing on environmental protection services for polluted soils, facilities and waters, remediation and monitoring of (large) tank facilities, as well as full-service engineering services for (LNG and hydrogen) tank facilities.
Wolftank-Adisa: weekly performance: 0.00%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (12/04/2021)




 

Bildnachweis

Aktien auf dem Radar:Rosenbauer, Porr, Strabag, Zumtobel, S Immo, Warimpex, Amag, Verbund, Addiko Bank, Erste Group, Frequentis, Cleen Energy, FACC, Hutter & Schrantz, Polytec Group, UIAG, UBM, Rath AG, Telekom Austria, Linz Textil Holding, Oberbank AG Stamm, CA Immo, Kapsch TrafficCom, Deutsche Wohnen.


Random Partner

Porr
Die Porr ist eines der größten Bauunternehmen in Österreich und gehört zu den führenden Anbietern in Europa. Als Full-Service-Provider bietet das Unternehmen alle Leistungen im Hoch-, Tief- und Infrastrukturbau entlang der gesamten Wertschöpfungskette Bau.

>> Besuchen Sie 64 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten